ストックスクリーナーアプリを入手
26.49
1.01%
0.27
前日終値:
$26.22
開ける：
$26.26
24時間の取引高:
1.86M
Relative Volume:
0.86
時価総額：
$11.81B
収益：
$2.24B
当期純損益:
$673.24M
株価収益率:
235.47
EPS:
0.1125
ネットキャッシュフロー:
$2.67B
1週間 パフォーマンス:
+3.54%
1か月 パフォーマンス:
-4.56%
6か月 パフォーマンス:
-2.52%
1年 パフォーマンス:
-1.91%
1日の値動き範囲:
$26.23
$26.66
1週間の範囲:
$25.10
$26.66
52週間の値動き範囲:
$25.10
$31.66
Royalty Pharma Plc Stock (RPRX) Company Profile
名前
Royalty Pharma Plc
セクター
電話
(212) 883-0200
住所
110 EAST 59TH STREET, NEW YORK, NY
RPRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| RPRX | 26.50 | 11.81B | 2.24B | 673.24M | 2.67B | 0.1125 |
| VRTX | 450.39 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 749.43 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.59 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.81 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.90 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-06-03 | ダウングレード | UBS | Buy → Neutral |
| 2022-06-14 | 再開されました | UBS | Buy |
| 2022-05-13 | 開始されました | Scotiabank | Sector Outperform |
| 2022-04-27 | 開始されました | Goldman | Buy |
| 2022-04-14 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2021-10-29 | アップグレード | Citigroup | Neutral → Buy |
| 2021-07-30 | 開始されました | Tigress Financial | Buy |
| 2020-11-09 | アップグレード | UBS | Neutral → Buy |
| 2020-07-14 | 開始されました | Evercore ISI | In-line |
| 2020-07-13 | 開始されました | BofA Securities | Buy |
| 2020-07-13 | 開始されました | Citigroup | Neutral |
| 2020-07-13 | 開始されました | Cowen | Outperform |
| 2020-07-13 | 開始されました | Goldman | Neutral |
| 2020-07-13 | 開始されました | JP Morgan | Neutral |
| 2020-07-13 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 開始されました | SunTrust | Buy |
| 2020-07-13 | 開始されました | UBS | Neutral |
すべてを表示
Royalty Pharma Plc (RPRX) 最新ニュース
Royalty Pharma (NASDAQ:RPRX) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Victory Capital Management Inc. Boosts Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Amalgamated Bank Sells 48,057 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Undercovered Dozen: Aurora Cannabis, FREYR Battery, Royalty Pharma, Talos Energy + - Seeking Alpha
Royalty Pharma stock hits 52-week low at $25.2 amid market shifts - Investing.com India
Royalty Pharma (NASDAQ:RPRX) Sets New 52-Week LowTime to Sell? - MarketBeat
Simplify Asset Management Inc. Increases Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
(RPRX) Technical Data - Stock Traders Daily
Royalty Pharma Announces Inaugural Prize for Impact in Healthcare - The Manila Times
Royalty Pharma Awards Inaugural Healthcare Prize to Michael Milken for Cancer Research Impact | RPRX Stock News - StockTitan
3 High-Yield Dividend Stocks You Can Buy With $130 Now and Hold at Least a Decade - The Motley Fool
Ex-Dividend Reminder: Cencora, Royalty Pharma and Brookline Bancorp - Nasdaq
Solid Earnings May Not Tell The Whole Story For Royalty Pharma (NASDAQ:RPRX) - Simply Wall St
Royalty Pharma's (NASDAQ:RPRX) Profits May Not Reveal Underlying Issues - Yahoo Finance
Syndax shares slide despite pivotal trial success - The Pharma Letter
New South Capital Management Inc. Has $69.77 Million Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Baillie Gifford & Co. - MarketBeat
Los Angeles Capital Management LLC Lowers Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Van ECK Associates Corp Boosts Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma Q3 2024 Earnings Preview - MSN
Summit Global Investments Purchases New Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Executive Wealth Management LLC - MarketBeat
Royalty Pharma Stock: Massive Opportunity Ahead (NASDAQ:RPRX) - Seeking Alpha
Morgan Stanley's Strategic Reduction in Royalty Pharma PLC Holdi - GuruFocus.com
Royalty Pharma plc (NASDAQ:RPRX) Q3 2024 Earnings Call Transcript - Insider Monkey
Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million - The Manila Times
Royalty Pharma plc (RPRX) to Acquire Royalty Interest in Geron’s (GERN) RYTELO for $125M - StreetInsider.com
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million - StockTitan
Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by Robeco Institutional Asset Management B.V. - MarketBeat
Royalty Pharma PLC (RPRX) Q3 2024 Earnings Call Highlights: Strong Growth and Strategic Acquisitions - Investing.com Canada
Royalty Pharma PLC (RPRX): A Strategic SWOT Insight - Yahoo Finance
Royalty Pharma Reports Strong Q3 2024 Results - TipRanks
Compared to Estimates, Royalty Pharma (RPRX) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Earnings call: Royalty Pharma reports robust Q3 growth, raises guidance By Investing.com - Investing.com Nigeria
Royalty Pharma reports robust Q3 growth, raises guidance By Investing.com - ழ தொலைக்காட்சி
Earnings call: Royalty Pharma reports robust Q3 growth, raises guidance - Investing.com
Royalty Pharma Reports Third Quarter 2024 Results - ForexTV.com
Royalty Pharma plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Royalty Pharma Q3 Soars: 15% Revenue Growth, $1.2B Deployment Drives Guidance Boost | RPRX Stock News - StockTitan
Tesla Inc (TSLA-Q) QuotePress Release - The Globe and Mail
River Road Asset Management LLC Has $13.30 Million Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals - Citeline News & Insights
Insights Ahead: Royalty Pharma's Quarterly Earnings - Benzinga
Royalty Pharma (NASDAQ:RPRX) Raised to “Buy” at StockNews.com - Defense World
Syndax agrees funding with Royalty Pharma for Niktimvo US sales - Yahoo Finance
Royalty Pharma plc and Syndax Pharmaceuticals Enter into $350 Million Royalty Funding Agreement for Niktimvo - Marketscreener.com
Royalty Pharma (NASDAQ:RPRX) Upgraded at StockNews.com - MarketBeat
Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo - The Manila Times
Syndax secures $350 million in royalty funding from Royalty Pharma By Investing.com - Investing.com UK
Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™ - StockTitan
With 72% ownership, Royalty Pharma plc (NASDAQ:RPRX) boasts of strong institutional backing - Simply Wall St
Royalty Pharma Plc (RPRX) 財務データ
収益
当期純利益
現金流量
EPS
Royalty Pharma Plc (RPRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| RIGGS RORY B | Director |
Jan 03 '24 |
Sale |
27.79 |
199,098 |
5,532,276 |
55,801 |
| RIGGS RORY B | Director |
Jan 04 '24 |
Sale |
27.55 |
35,702 |
983,504 |
20,099 |
| Avara Management Ltd | 10% Owner |
Dec 29 '23 |
Sale |
28.04 |
65,803 |
1,845,406 |
2,477,520 |
| Avara Management Ltd | 10% Owner |
Dec 28 '23 |
Sale |
28.20 |
209,863 |
5,918,934 |
2,543,323 |
| Avara Management Ltd | 10% Owner |
Dec 27 '23 |
Sale |
28.01 |
41,729 |
1,168,754 |
2,753,186 |
| Avara Management Ltd | 10% Owner |
Dec 15 '23 |
Sale |
28.01 |
10,229 |
286,499 |
2,794,915 |
| Avara Management Ltd | 10% Owner |
Dec 14 '23 |
Sale |
28.91 |
364,441 |
10,534,276 |
2,805,144 |
| Avara Management Ltd | 10% Owner |
Dec 13 '23 |
Sale |
28.95 |
307,935 |
8,916,012 |
3,169,585 |
1.80%
0.42%
大文字化:
|
ボリューム (24 時間):